Merz Aesthetics

Where Merz Aesthetics fits

Merz Aesthetics is the third major injectables house on the US med-spa shelf, and it competes by being different rather than by being biggest. Run from a US headquarters in Raleigh under a family-owned German parent founded in 1908, Merz is the world's largest company dedicated purely to medical aesthetics — no pharma sidelines, no quarterly-earnings pressure. Its injectable lineup is compact: Xeomin, the 'naked' neurotoxin manufactured without complexing proteins; Radiesse, the leading calcium-hydroxylapatite biostimulator; and the Belotero HA filler family. The Xperience+ program handles consumer loyalty and practice rewards. Merz's devices — most notably Ultherapy — are covered separately in our Equipment category and not re-reviewed here.

What stands out

• A toxin with a story. Xeomin's no-complexing-proteins formulation gives injectors a clean-label narrative and a theoretical lower-immunogenicity argument that lands well with ingredient-conscious patients — a genuinely distinct positioning in a category where differentiation is hard.
• Radiesse. The leading CaHA biostimulator is Merz's strongest asset. It competes directly with Sculptra for the regenerative slot, offers immediate volumization plus collagen stimulation, and (in hyperdilute protocols) has become a staple of skin-quality menus. Any practice serious about biostimulators should be comparing Radiesse and Sculptra side by side.
• Belotero's niche. The family's smooth tissue integration makes it a go-to for fine lines, perioral etching and delicate areas where firmer HA gels can lump — a useful complement to bolder filler lines rather than a full replacement.
• Negotiating leverage and support. Merz frequently competes hard on effective acquisition cost, and med spas report that a credible Merz relationship improves the tenor of their Allergan and Galderma negotiations. Training through the Merz Institute and rep-led onboarding are solid.

Where it falls short

• Brand pull. This is the honest trade-off. Patients rarely walk in asking for Xeomin or Belotero by name; practices leading with Merz products carry more of the patient-education burden themselves, and menu marketing has to work harder.
• Portfolio gaps. The Belotero range is narrower than Juvéderm or Restylane, with fewer indication-specific options for lips, chin and jawline; most Merz accounts still pair with another filler family.
• Loyalty scale. Xperience+ is functional but is the smallest of the big-three programs, so its retention economics are weaker than Allē's or ASPIRE's.
• The usual opacity. Pricing is rep-negotiated with no public list, and Merz's field coverage, while good, is thinner than the top two — smaller markets can see less frequent rep attention.

Who should choose it

Merz Aesthetics makes most sense as a strategic second or third account. Choose it if Radiesse anchors your regenerative menu, if the Xeomin clean-label story fits your patient base, or if you want real pricing leverage across your injectables procurement. It can serve as a primary toxin house for cost-focused practices willing to invest in patient education, but most med spas will run Merz alongside Allergan and/or Galderma rather than instead of them. As with all three majors, a licensed prescriber or medical director is required to open the account, and net-of-rebate economics — not list price — should drive the decision.